The burgeoning popularity of retatrutide, initially for metabolic conditions, is creating significant attention within the United Kingdom , prompting a notable shift in peptide trends. Availability these medications remains a complex landscape, with public healthcare system provision currently limited and specialist practices offering therapy at a